1. Home
  2. ERO vs ZYME Comparison

ERO vs ZYME Comparison

Compare ERO & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ERO
  • ZYME
  • Stock Information
  • Founded
  • ERO 2016
  • ZYME 2003
  • Country
  • ERO Canada
  • ZYME United States
  • Employees
  • ERO N/A
  • ZYME N/A
  • Industry
  • ERO
  • ZYME Biotechnology: Pharmaceutical Preparations
  • Sector
  • ERO
  • ZYME Health Care
  • Exchange
  • ERO Nasdaq
  • ZYME Nasdaq
  • Market Cap
  • ERO 1.5B
  • ZYME 1.2B
  • IPO Year
  • ERO N/A
  • ZYME 2017
  • Fundamental
  • Price
  • ERO $21.49
  • ZYME $19.12
  • Analyst Decision
  • ERO Strong Buy
  • ZYME Strong Buy
  • Analyst Count
  • ERO 1
  • ZYME 9
  • Target Price
  • ERO $25.00
  • ZYME $22.88
  • AVG Volume (30 Days)
  • ERO 1.2M
  • ZYME 882.8K
  • Earning Date
  • ERO 11-04-2025
  • ZYME 11-06-2025
  • Dividend Yield
  • ERO N/A
  • ZYME N/A
  • EPS Growth
  • ERO N/A
  • ZYME N/A
  • EPS
  • ERO 1.38
  • ZYME N/A
  • Revenue
  • ERO $535,974,000.00
  • ZYME $122,867,000.00
  • Revenue This Year
  • ERO $64.70
  • ZYME $99.52
  • Revenue Next Year
  • ERO $31.18
  • ZYME N/A
  • P/E Ratio
  • ERO $15.54
  • ZYME N/A
  • Revenue Growth
  • ERO 20.59
  • ZYME 95.94
  • 52 Week Low
  • ERO $9.30
  • ZYME $9.03
  • 52 Week High
  • ERO $24.48
  • ZYME $19.50
  • Technical
  • Relative Strength Index (RSI)
  • ERO 51.58
  • ZYME 73.72
  • Support Level
  • ERO $20.20
  • ZYME $17.27
  • Resistance Level
  • ERO $22.13
  • ZYME $19.42
  • Average True Range (ATR)
  • ERO 0.99
  • ZYME 0.77
  • MACD
  • ERO -0.37
  • ZYME 0.08
  • Stochastic Oscillator
  • ERO 20.07
  • ZYME 88.19

About ERO Ero Copper Corp.

Ero Copper Corp is a base metals mining company. It is predominantly focused on the production and sale of copper with gold and silver produced and sold as by-products. Ero's operations are segmented between its mines in Brazil, the Caraiba Operations and the Xavantina Operations, its development project, the Tucuma Project in Brazil and corporate. Majority of its revenue is generated from its Caraiba Operations segment which consists of mining operations and processing facilities including the Pilar and Vermelhos underground mines and the Surubim open pit mine.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: